Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec’s Reports Of Tysabri Side Effects Don’t Rattle FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Wall Street reacted sharply to disclosure of two new PML cases associated with Tysabri, but it doesn’t sound like FDA plans a regulatory response.

You may also be interested in...



FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use

FDA appears to be setting new policy on when drugs should be available for compassionate use

FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use

FDA appears to be setting new policy on when drugs should be available for compassionate use

FDA Still Behind Tysabri Monotherapy

Medwatch warning is less strident than some feared.

Related Content

Topics

UsernamePublicRestriction

Register

OM017315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel